The peptide market is continually developing, but how are manufacturers responding to its new requirements and altering the landscape of peptide manufacturing?

Competition between cosmetic treatments begins.

Vyepti is the first intravenous medication approved for migraine treatment.

Nazneen Dewji, President and CEO of Cenna Biosciences leads a discussion on the strategies to overcome the challenges ‘Oral Delivery of Peptides’.

In this Commentary article, we explore how innovative technologies like expression tags could help to overcome challenges associated with recombinant peptide production. The potential for recombinant production to slash manufacturing costs has made it a focal area of research for companies such as Boehringer Ingelheim.

UCB, Bicycle Therapeutics, and Sanofi share their latest findings in Peptide discovery at Biologics UK 2022.